2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported dataDepot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk
Phung M, Lee A, Wu A, Berchuck A, Cho K, Cramer D, Doherty J, Goodman M, Hanley G, Harris H, McLean K, Modugno F, Moysich K, Mukherjee B, Schildkraut J, Terry K, Titus L, Consortium O, Jordan S, Webb P, Consortium O, Pike M, Pearce C. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 927-935. PMID: 33619020, PMCID: PMC9281627, DOI: 10.1158/1055-9965.epi-20-1355.Peer-Reviewed Original ResearchConceptsOvarian cancer riskDepot medroxyprogesterone acetate useRisk of ovarian cancerDepot medroxyprogesterone acetateCancer riskOvarian cancerDecreased riskInverse associationRisk of invasive epithelial ovarian cancerRisk of ovarian cancer overallAssociated with decreased risk of ovarian cancerDecreased risk of ovarian cancerOvarian Cancer Association ConsortiumDecreased ovarian cancer riskSystematic reviewOvarian cancer overallInvasive epithelial ovarian cancerAssociated with decreased riskCombined oral contraceptive useInjectable progestin-only contraceptivesProgestin-only contraceptive useProgestin-releasing intrauterine deviceContraceptive useAssociated with ovarian cancerProgestin-only contraceptives
2020
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
Lee AW, Rosenzweig S, Wiensch A, Group T, Ramus SJ, Menon U, Gentry-Maharaj A, Ziogas A, Anton-Culver H, Whittemore AS, Sieh W, Rothstein JH, McGuire V, Wentzensen N, Bandera EV, Qin B, Terry KL, Cramer DW, Titus L, Schildkraut JM, Berchuck A, Goode EL, Kjaer SK, Jensen A, Jordan SJ, Ness RB, Modugno F, Moysich K, Thompson PJ, Goodman MT, Carney ME, Chang-Claude J, Rossing MA, Harris HR, Doherty JA, Risch HA, Khoja L, Alimujiang A, Phung MT, Brieger K, Mukherjee B, Pharoah PDP, Wu AH, Pike MC, Webb PM, Pearce CL. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal Of The National Cancer Institute 2020, 113: 301-308. PMID: 32766851, PMCID: PMC7936053, DOI: 10.1093/jnci/djaa099.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive epithelial ovarian cancerClear cell ovarian cancerIncomplete pregnanciesEpithelial ovarian cancerOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioInvasive epithelial ovarian cancer casesEpithelial ovarian cancer casesHistotype-specific analysesHistotype-specific associationsOral contraceptive useInvasive ovarian cancerHistory of breastfeedingConfidence intervalsOvarian cancer casesCase-control studyOCAC studiesMajor histotypesPooled analysisInverse associationCancer casesComplete pregnancy
2019
Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
Idos G, Kurian A, Ricker C, Sturgeon D, Culver J, Kingham K, Koff R, Chun N, Rowe-Teeter C, Lebensohn A, Levonian P, Lowstuter K, Partynski K, Hong C, Mills M, Petrovchich I, S. C, Hartman A, Allen B, Wenstrup R, Lancaster J, Brown K, Kidd J, Evans B, Mukherjee B, McDonnell K, Ladabaum U, Ford J, Gruber S. Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology 2019, 3: po.18.00217. PMID: 34322651, PMCID: PMC8260917, DOI: 10.1200/po.18.00217.Peer-Reviewed Original ResearchMultiplex gene panel testProspective cohort studyGene panel testingPatient experiencePathogenic variantsDiagnostic yieldCohort studyNorris Comprehensive Cancer CenterHereditary cancer riskSocioeconomically diverse cohortComprehensive cancer centerPost-test surveysPanel testingCancer susceptibility genesMulticenter prospective cohort studyLos Angeles CountyUniversity of Southern California Medical CenterIdentified pathogenic variantsCancer riskSouthern California Medical CenterLess educationPatient regretProphylactic surgeryExpert clinical assessmentCalifornia Medical Center
2017
Opportunities and Challenges for Environmental Exposure Assessment in Population-Based Studies
Patel C, Kerr J, Thomas D, Mukherjee B, Ritz B, Chatterjee N, Jankowska M, Madan J, Karagas M, McAllister K, Mechanic L, Fallin M, Ladd-Acosta C, Blair I, Teitelbaum S, Amos C. Opportunities and Challenges for Environmental Exposure Assessment in Population-Based Studies. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1370-1380. PMID: 28710076, PMCID: PMC5581729, DOI: 10.1158/1055-9965.epi-17-0459.Peer-Reviewed Original ResearchConceptsFollow-up of study participantsInfluence cancer riskExposure and behaviourPopulation-based studyExposure assessmentCase-control studyPhysical activityCancer riskCorrelated exposuresStudy participantsEpidemiological studiesGenetic susceptibilityEnvironmental exposure assessmentFollow-upData collectionMultidimensional indicatorsCancer developmentEvaluated 1Indicators of exposureComplex effects of environmental factorsEpidemiological investigationsOccupational exposure assessmentAssessmentEnvironmental factorsDisease development
2016
A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
Lee A, Bomkamp A, Bandera E, Jensen A, Ramus S, Goodman M, Rossing M, Modugno F, Moysich K, Chang‐Claude J, Rudolph A, Gentry‐Maharaj A, Terry K, Gayther S, Cramer D, Doherty J, Schildkraut J, Kjaer S, Ness R, Menon U, Berchuck A, Mukherjee B, Roman L, Pharoah P, Chenevix‐Trench G, Olson S, Hogdall E, Wu A, Pike M, Stram D, Pearce C, Consortium F. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal Of Cancer 2016, 139: 2646-2654. PMID: 27420401, PMCID: PMC5500237, DOI: 10.1002/ijc.30274.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAllelesAlternative SplicingCase-Control StudiesDisease SusceptibilityEstrogen Replacement TherapyFemaleGene-Environment InteractionGenome-Wide Association StudyGenotypeHumansMenopauseMiddle AgedOdds RatioOvarian NeoplasmsPolymorphism, Single NucleotidePopulation SurveillanceRiskTelomeraseConceptsOvarian Cancer Association ConsortiumEstrogen-alone therapyOvarian cancer riskEndometrioid ovarian cancerOvarian cancerET usersET useT alleleAssociated with ovarian cancer riskCancer riskLong-term ET usersOvarian cancer susceptibility lociRisk of ovarian cancerSusceptibility variantsMenopausal estrogen therapyCancer susceptibility lociSerous ovarian cancerSplice variantsNon-usersCase-control studyConditional logistic regressionGenome-wide association studiesIncreased risk of diseaseEndometrioid histotypeEstrogen therapy
2014
Personal exposure to mixtures of volatile organic compounds: modeling and further analysis of the RIOPA data.
Batterman S, Su F, Li S, Mukherjee B, Jia C. Personal exposure to mixtures of volatile organic compounds: modeling and further analysis of the RIOPA data. Research Report 2014, 3-63. PMID: 25145040, PMCID: PMC4577247.Peer-Reviewed Original ResearchConceptsPositive matrix factorizationCumulative cancer riskAir exchange rateVOC exposureToxicological mode of actionMethod detection limitsPersonal exposureVolatile organic compoundsOutdoor concentrationsVOC mixturesVOC concentrationsEmission sourcesEmission sources of volatile organic compoundsHome air exchange ratesLinear mixed-effects modelsSources of volatile organic compoundsLifetime cumulative cancer riskToxicological modeVOC dataIndividual VOCsVariables associated with exposureRelationship of IndoorIndoor VOC concentrationsCancer riskHealth-based guidelines
2013
FADS genotype affects change in fatty acid levels after a Mediterranean dietary intervention
Djuric Z, Porenta S, Ren J, Ko Y, Baylin A, Mukherjee B, Gruber S. FADS genotype affects change in fatty acid levels after a Mediterranean dietary intervention. The FASEB Journal 2013, 27: 372.5-372.5. DOI: 10.1096/fasebj.27.1_supplement.372.5.Peer-Reviewed Original ResearchFatty acid levelsProstaglandin E2Allele carriersColonic mucosaFADS genotypesIntake of n-3Increased colon cancer riskIntake of n-6 fatty acidsMediterranean dietary interventionAcid levelsColon cancer riskMinor allele carriersSerum arachidonic acidFatty acidsFatty acid desaturaseN-6 fatty acid levelsPro-inflammatory eicosanoidsColon cancerDietary interventionFADS clusterN-9 fatty acidsCancer riskMediterranean dietLowered intakeN-6 fatty acidsElevated Risk of Prostate Cancer Among Men With Lynch Syndrome
Raymond V, Mukherjee B, Wang F, Huang S, Stoffel E, Kastrinos F, Syngal S, Cooney K, Gruber S. Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. Journal Of Clinical Oncology 2013, 31: 1713-1718. PMID: 23530095, PMCID: PMC3641694, DOI: 10.1200/jco.2012.44.1238.Peer-Reviewed Original ResearchConceptsLynch syndromeCumulative lifetime riskRisk of prostate cancerAge-specific cumulative riskLifetime risk of prostate cancerFamilial cancer registryGeneral populationHazard ratioCumulative risk of prostate cancerModified segregation analysisProstate cancerFourth-degree relativesCumulative riskProstate cancer riskLS familiesCancer RegistryCancer riskLifetime riskCases of prostate cancerPopulation riskMismatch repair-deficient phenotypeWald-type CICancer diagnosisMutation carriersElevated risk
2009
Risk of Pancreatic Cancer in Families With Lynch Syndrome
Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond V, Bandipalliam P, Stoffel E, Gruber S, Syngal S. Risk of Pancreatic Cancer in Families With Lynch Syndrome. JAMA 2009, 302: 1790-1795. PMID: 19861671, PMCID: PMC4091624, DOI: 10.1001/jama.2009.1529.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overColorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairDNA Mutational AnalysisDNA-Binding ProteinsFemaleGenotypeGerm-Line MutationHumansMaleMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinNuclear ProteinsPancreatic NeoplasmsPedigreePhenotypeProportional Hazards ModelsRegistriesRiskSEER ProgramYoung AdultConceptsRisk of pancreatic cancerMutations of DNA mismatch repairPancreatic cancer riskGermline MMR gene mutationsMMR gene mutationsCancer riskHazard ratio estimatesLynch syndromeInherited cause of colorectal cancerAge-specific cumulative riskCumulative riskCumulative risk of pancreatic cancerFamily history of pancreatic cancerHistory of pancreatic cancerFamilial cancer registryGeneral populationModified segregation analysisCause of colorectal cancerUniversity of Michigan Comprehensive Cancer CenterComprehensive cancer centerGene mutation carriersCases of pancreatic cancerStudy start dateDana-Farber Cancer InstituteExtracolonic tumors